NEW YORK (TheStreet) -- AtriCure (ATRC) was one of several stocks trading near $5 poised to move on above-average volume Tuesday after the company's heart device received regulatory clearance in the U.S.
AtriCure said the Food and Drug Administration gave clearance to its AtriClip system, which is designed to be implanted from the outside of the heart, avoiding contact with circulating blood and eliminating blood flow between the left atrial appendage and the atria.
AtriCure said the initial launch of the AtriClip system in the U.S. is expected to begin later this month with full commercial release planned during the third quarter of 2010.
AtriCure shares jumped by 92 cents, or 17.6%, to $6.15 in the premarket session. The 50-day average daily volume for AtriCure is 27,000, according to the Nasdaq.Elsewhere, Synergetics USA (SURG) rose by 18 cents, or 6.6%, to $2.91 in the premarket session after the medical device company posted third-quarter earnings of 13 cents a share, which is up from a profit of 3 cents a share in the year-ago period. The 50-day average daily volume for Synergetics is 135,000.
|More on Biotech 14 Biotech Stocks Facing FDA Approval|
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV